Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for PGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 26.69M
March 31, 2026 20.97M
December 31, 2025 39.87M
September 30, 2025 -63.39M
June 30, 2025 28.44M
March 31, 2025 -6.457M
December 31, 2024 -65.37M
September 30, 2024 5.653M
June 30, 2024 14.96M
March 31, 2024 24.04M
December 31, 2023 13.29M
September 30, 2023 10.52M
June 30, 2023 23.50M
March 31, 2023 -50.41M
December 31, 2022 11.42M
September 30, 2022 181.86M
June 30, 2022 16.57M
March 31, 2022 16.57M
December 31, 2021 15.93M
September 30, 2021 22.01M
June 30, 2021 16.62M
March 31, 2021 -129.10M
December 31, 2020 40.18M
September 30, 2020 0.181M
June 30, 2020 23.97M
Date Value
March 31, 2020 -36.55M
December 31, 2019 54.51M
September 30, 2019 13.78M
June 30, 2019 -15.03M
March 31, 2019 33.59M
December 31, 2018 30.74M
September 30, 2018 -161.03M
June 30, 2018 -13.46M
March 31, 2018 -7.456M
December 31, 2017 23.91M
September 30, 2017 28.14M
June 30, 2017 17.73M
March 31, 2017 33.64M
December 31, 2016 16.75M
September 30, 2016 -63.77M
June 30, 2016 14.74M
March 31, 2016 3.88M
December 31, 2015 -3.493M
September 30, 2015 -239.51M
June 30, 2015 8.225M
March 31, 2015 -26.03M
December 31, 2014 10.46M
September 30, 2014 -39.75M
June 30, 2014 -22.60M
March 31, 2014 25.86M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. -1.28M
Geron Corp. 8.295M
Neurocrine Biosciences, Inc. -135.40M
Aldeyra Therapeutics, Inc. -0.0231M
Elicio Therapeutics, Inc. 0.00